Drug Trial Radar · NCT07192666
Exosomes in Patients With Ocular Involvement of Sjögren's Syndrome
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Sep 15, 2025
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-center, multiple-dosing, prospective, nonrandom, single-arm trial.
Conditions
- Sjögren's Syndrome
Interventions
Exosome PreparationDrug
Each subject will have a single designated study eye; this eye will receive multiple instillations-one drop four times daily for 14 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: from subjects receiving administration to Day 29 post-administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.